高级检索
当前位置: 首页 > 详情页

Potential of β-elemene induced ferroptosis through Pole2-mediated p53 and PI3K/AKT signaling in lung cancer cells

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Thoracic Surgery, Affiliated Hospital of Yunnan University, Kunming, 650000, China [2]Department of General Surgery, The 920 Hospital of PLA Joint Service Support Force, Kunming, 650000, China [3]Department of Respiratory and Critical Care MedicineII, The First Affiliated Hospital of Kunming Medical University, Kunming, 650000, China [4]Department of Respiratory, Affiliated Hospital of Yunnan University, Kunming, 650000, China [5]Department of Biophysics, PGIMER, Chandigarh, India
出处:
ISSN:

关键词: Pole2 Lung cancer β -elemene PI3K AKT

摘要:
Ferroptosis is crucial for tumor growth inhibition. Moreover, ferroptosis has been considered as a potential strategy against cancer. The present study focused on the mechanism of ferroptosis induction by β-elemene during the lung cancer (extracted from the Chinese medicine Curcuma Wen yujin). CCK-8 assay, flow cytometry and biochemical assays including intracellular ROS, MDA, GSH, iron and 8-OHdG level were performed. DNA polymerase epsilon subunit 2 (Pole2) and the ferroptosis-related proteins were studied by utilizing western blotting. The study results showed that the β-elemene reduced the viability of lung cancer cells via ferroptosis. Furthermore, multiple experiments confirmed that Pole2 knockdown enhanced the production of lipid ROS, MDA and iron, leading to the iron-dependent ferroptosis in lung cancer cells. Overexpression of Pole2 inhibited β-elemene-induced ferroptosis through reduction of iron-dependent oxidative damage. Mechanically, Pole2 reduced the upregulation of p53 expression, and increased the phosphorylation levels of PI3K and AKT in β-elemene-induced cells. Overexpression of TP53 or the inhibitor of PI3K/AKT pathway reversed the effects of Pole2. Together, β-elemene evoked ferroptosis through the Pole2-regulated p53 or PI3K/AKT signalling, and might be an effective therapy for lung carcinogenesis.Copyright © 2022 Elsevier B.V. All rights reserved.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 2 区 医学
小类 | 2 区 药学 2 区 生化与分子生物学 2 区 毒理学
最新[2025]版:
大类 | 2 区 医学
小类 | 1 区 毒理学 2 区 生化与分子生物学 2 区 药学
JCR分区:
出版当年[2021]版:
Q1 TOXICOLOGY Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q1 PHARMACOLOGY & PHARMACY Q1 TOXICOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Department of Thoracic Surgery, Affiliated Hospital of Yunnan University, Kunming, 650000, China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:87463 今日访问量:2 总访问量:721 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号